IGC Pharma (IGC) Total Non-Current Liabilities (2011 - 2026)
IGC Pharma (IGC) reported Total Non-Current Liabilities of $191000.0 for Q1 2026, up 19.38% year-over-year from $160000.0 in Q1 2025, and up 43.61% quarter-over-quarter from $133000.0 in Q4 2025.
IGC Pharma (IGC) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has 16 years of Total Non-Current Liabilities data on file, last reported at $191000.0 in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $191000.0, up 19.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $191000.0 (up 19.38% YoY), and the FY2026 annual result was $191000.0, up 19.38% from the prior year.
- Total Non-Current Liabilities climbed to $191000.0 in Q1 2026 per IGC's latest filing, from $133000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $501000.0 in Q1 2022 and troughed at $133000.0 in Q4 2025.
- A 5-year average of $273941.2 and a median of $241000.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities tumbled 40.0% in 2024, then rose 19.38% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $397000.0 in 2022, then sank by 31.99% to $270000.0 in 2023, then plunged by 40.0% to $162000.0 in 2024, then declined by 17.9% to $133000.0 in 2025, then surged by 43.61% to $191000.0 in 2026.
- Business Quant data shows IGC's Total Non-Current Liabilities at $191000.0 in Q1 2026, $133000.0 in Q4 2025, and $137000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 64.76 Mn |
| 10 | IGC Pharma | 29.33 Mn | 29.07 Mn | - | 191,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 191,000.00 |
| Dec 31, 2025 | 133,000.00 |
| Sep 30, 2025 | 137,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 160,000.00 |
| Dec 31, 2024 | 162,000.00 |
| Sep 30, 2024 | 190,000.00 |
| Jun 30, 2024 | 225,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Dec 31, 2023 | 270,000.00 |
| Sep 30, 2023 | 302,000.00 |
| Jun 30, 2023 | 340,000.00 |
| Mar 31, 2023 | 369,000.00 |
| Dec 31, 2022 | 397,000.00 |
| Sep 30, 2022 | 432,000.00 |
| Jun 30, 2022 | 467,000.00 |
| Mar 31, 2022 | 501,000.00 |
| Dec 31, 2021 | 534,000.00 |
| Sep 30, 2021 | 565,000.00 |
| Jun 30, 2021 | 595,000.00 |